Author:
Lazzeroni M,Guerrieri-Gonzaga A,Botteri E,Leonardi M C,Rotmensz N,Serrano D,Varricchio C,Disalvatore D,Castillo A Del,Bassi F,Pagani G,DeCensi A,Viale G,Bonanni B,Pruneri G
Publisher
Springer Science and Business Media LLC
Reference53 articles.
1. Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, Mamounas EP, Julian TB, Geyer CE Jr, Costantino JP, Land SR, Wolmark N (2012) Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol 30: 1268–1273.
2. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T The ATAC (Arimidex TaoiCTG) (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (arimidex, tamoxifen alone or in combination) trial efficacy and safety update analyses. Cancer 98: 1802–1810.
3. Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van H I, Julien JP, Gennaro M, Rouanet P, Avril A, Fentiman IS, Bartelink H, Rutgers EJ (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24: 3381–3387.
4. Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Kandioler-Eckersberger D, Gnant M, Jakesz R (2001) Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 7: 1669–1675.
5. Boughey JC, Gonzalez RJ, Bonner E, Kuerer HM (2007) Current treatment and clinical trial developments for ductal carcinoma in situ of the breast. Oncologist 12: 1276–1287.
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献